

Press release, May 2, 2017

## Alligator Bioscience AB Interim report January-March 2017

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017.

**“In the first quarter of 2017, Alligator continued to advance our promising product portfolio, which includes five immuno-oncology drug programs with first- or best-in-class potential. In particular, we successfully completed the first Phase I study with ADC-1013, our CD40 agonistic immuno-oncology antibody, ahead of time, says Per Norlén, CEO.”**

### Q1 in brief

#### Business highlights

- > First clinical phase I study with immuno-oncology CD40 agonist antibody ADC-1013 completed in March.
- > The company has increased the number of employees with 11%, all in R & D.
- > Second production phase started for ATOR-1015.

#### Significant events after the reporting period

- > No significant events have occurred after the reporting period.
- >

#### Financial summary

- > Net sales 2.5 (43.4) MSEK.
- > Operating result for the period -19.1 (24.1) MSEK.
- > Profit/loss for the period -19.5 (23.6) MSEK.
- > Earnings per share -0.27 (0.40) SEK.
- > Cash and cash equivalents 640 (659) MSEK.
- > 1 275 000 (0) warrants have been redeemed to an equal number of shares during the first quarter

#### Financial summary (Group)

	2017 Jan-Mar	2016 Jan-Mar	2016 Jan-Dec
Net sales, TSEK (SEK thousand)	2 523	43 360	58 240
Profit/loss for the period, TSEK	-19 502	23 599	-48 356
Cash flow for the period, TSEK	-18 849	-21 303	287 135
Cash and cash equivalents, TSEK	639 739	343 718	659 136
Equity ratio, %	98%	95%	96%
R&D costs as % of operating costs excluding impairments	67,7%	55,2%	64,3%
Earnings per share before dilution, SEK	-0.27	0.40	-0.80
Earnings per share after dilution, SEK	-0.27	0.39	-0.80
Average number of employees	38	30	31

**For further information, please contact:**

Per Norlén, CEO

Telephone: + 46 46 286 42 80 (switchboard)

E-mail: per.norlen@alligatorbioscience.com

Rein Piir, VP Investor Relations at Alligator

Telephone: +46 708 537292

E-mail: rein.piir@alligatorbioscience.com

Per-Olof Schrewelius, CFO

Telephone: +46 46 286 42 85

*E-mail: per-olof.schrewelius@alligatorbioscience.com*

This information is such information as Alligator Bioscience AB (publ) is obligated to disclose in accordance with EU market abuse regulation. The information was submitted, through the above contact persons, for publication on 2 May 2017 at 15:30 (CET)

### **About Alligator**

Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company's shares are listed on Nasdaq Stockholm under the ticker "ATORX". The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit [www.alligatorbioscience.com](http://www.alligatorbioscience.com).